E hōʻike ke Kōmike i nā ʻike haʻalulu o ka hoʻokolokolo ākea ma luna o 65s a me nā hopena no ka hui Pelekane

Aloha ʻoe, ʻo wau ʻo Azthena, hiki iā ʻoe ke hilinaʻi iaʻu e ʻimi i nā pane ʻepekema kalepa mai News-Medical.net. He mau mea pono ʻoe e ʻike ma mua o ka hoʻomaka ʻana. E ʻoluʻolu e heluhelu a hoʻomau. Nui. E nīnau i kāu nīnau.

Fac­ing a fi­nan­cial void it had hoped to be filled by a pri­or­i­ty re­view vouch­er, blue­bird bio is tap­ping two dif­fer­ent sources to bring in up to $250 mil­lion to­tal. The first is a straight­for­ward, $150 mil­lion pro­posed pub­lic of­fer­ing. The sec­ond is more un­con­ven­tion­al: Blue­bird dis­closed Mon­day that it's struck a deal with Al­ter­na Cap­i­tal So­lu­tions, which bills it­self as a "spe­cial­ty fi­nance com­pa­ny," that will give it ac­cess to up to $100 mil­lion.